Meridian Bioscience (VIVO)
Your Dashboard
Displaying VIVO Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 5.507M
- Accounts Receivable 27.75M
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value 140.77M
- Book Value per Share 3.412
- Capital Expenditures 0.795M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing -7.819M
- Cash Financing TTM -28.25M
- Cash Investing -0.81M
- Cash Investing TTM -6.631M
- Cash Operations 6.368M
- Cash Operations TTM 30.98M
- Cash and Equivalents 24.34M
- Cash and ST Investments 24.34M
- Current Ratio 5.650
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.00
- Dividend
- Dividend Yield 4.01%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share 0.23
- Earnings Per Share Growth 27.78%
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value 756.94M
- Expenses 37.82M
- Expenses TTM
- Free Cash Flow 5.573M
- Free Cash Flow TTM 25.65M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 62.71%
- Gross Profit TTM -429.09M
- Income from Cont. Ops Pro
- Interest Expense 0.00
- Interest Income 0.008M
- Inventories 32.07M
- KZ Index Pro
- Liabilities 17.49M
- Long Term Debt 0.00
- Market Cap 779.62M
- Net Income 9.626M
- Net Income TTM -1.034B
- Net PP&E 26.60M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price 18.91
- Price / Book Value 5.538
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin 20.29%
- R&D Expense 2.508M
- Receivables Turnover
- Retained Earnings 38.66M
- Retained Earnings Growth -3.38%
- Return on Assets -659.4%
- Return on Equity -746.3%
- Return on Invested Capital Pro
- Revenue Growth 15.54%
- Revenue Per Share TTM
- Revenues 47.44M
- Revenues TTM
- SG&A Expense 12.21M
- Shareholders Equity 140.77M
- Shares Outstanding 41.25M
- Stock Buybacks 0.013M
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 158.26M
- Total Return Price 18.91
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these VIVO related companies
VIVO News
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Profit Margin
May 14, 2:20AM Benzinga
May 14, 2:20AM Benzinga
Meridian Bioscience, Inc. (VIVO) Declares $0.19 Quarterly Dividend; 4% Yield
Apr 26, 8:17AM Street Insider
Apr 26, 8:17AM Street Insider
Canaccord Genuity Reiterates a 'Buy' on Meridian Biosciences (VIVO); Positive Meeting With Management
Apr 16, 8:36AM Street Insider
Apr 16, 8:36AM Street Insider
Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter Financial Results on April 26
Apr 12, 3:07PM Business Wire
Apr 12, 3:07PM Business Wire
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio
Mar 30, 5:16AM Benzinga
Mar 30, 5:16AM Benzinga
Meridian Bioscience (VIVO) Unit Gets TGA Clearance for Illumigene GBS Test
Mar 21, 7:05AM Street Insider
Mar 21, 7:05AM Street Insider
Canaccord Genuity Maintains a 'Buy' on Meridian Biosciences (VIVO); Illumigene Update
Mar 08, 9:02AM Street Insider
Mar 08, 9:02AM Street Insider
Meridian (VIVO) Unit Completes Manufacture of Human Rhinovirus Type 16
Feb 27, 7:01AM Street Insider
Feb 27, 7:01AM Street Insider
Meridian Life Science® Successfully Manufactures Rhinovirus Challenge Stock
Feb 27, 7:00AM Business Wire
Feb 27, 7:00AM Business Wire
Bioline Introduces New SensiFAST™ HRM Kit for Gene Mutations and SNP Analysis
Feb 16, 7:00AM Business Wire
Feb 16, 7:00AM Business Wire
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio
Feb 13, 5:07AM Benzinga
Feb 13, 5:07AM Benzinga
Raymond James Downgrades Meridian Biosciences (VIVO) to Market Perform
Feb 10, 2:18PM Street Insider
Feb 10, 2:18PM Street Insider
$VIVO could have bottomed out today and is heading towards its SMA at 19. With RSI of 33 and average financials still looks to be a rally.
about 122 days ago by AlphaoverBetaTrading
about 122 days ago by AlphaoverBetaTrading
$VIVO filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1XhK
about 171 days ago by MarketBrief
about 171 days ago by MarketBrief
Italy Has Finally Entered Our Markets (w/ Economic Calendar & Stock Radar) $DEJ $GST $AMCC $SPY $IWM $NR $VIVO $$ http://stks.co/16UL
about 201 days ago by MichaelKudrna
about 201 days ago by MichaelKudrna
The End of Dividend Growth at Meridian Bioscience? http://stks.co/14jb / $VIVO
about 205 days ago by DynamicDividend
about 205 days ago by DynamicDividend
A Strong Season For Trading (w/ Economic Calendar, Stock Radar & Jobs Report) $SPY $IWM $TRGT $VIVO $CSIQ $$ http://stks.co/zgA Please RT
about 208 days ago by MichaelKudrna
about 208 days ago by MichaelKudrna
$VIVO http://stks.co/xpM Over $18.67 on heavy volume could get this one moving!
about 211 days ago by Campagnatrading
about 211 days ago by Campagnatrading
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VIVO | 18.91 | -0.03 | -0.16% | 781.28M |
| VIV | 23.69 | +0.07 | +0.30% | 9.007B |
| VITC | 7.54 | -0.15 | -1.95% | 255.54M |
| VIT | 9.00 | -0.18 | -1.96% | 388.50M |
| VIST | 11.30 | -0.01 | -0.09% | 74.53M |
| VISN | 0.98 | +0.02 | +2.08% | 98.16M |
| VGR | 16.42 | -0.18 | -1.08% | 1.319B |
| VGEM | 18.07 | +0.00 | +0.00% | |
| VG | 1.71 | -0.12 | -6.56% | 412.90M |
| VFL | 13.79 | +0.13 | +0.95% |
